PDK1 and hepatocellular carcinoma: Inhibition of pyruvate dehydrogenase kinase 1 using a small molecule, dicoumarol, increased the OXPHOS flux in HCC, which can enhance the sensitivity of oxaliplatin for HCC chemotherapy [40].